Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04820673 · ClinicalTrials.gov registry record
Patient-reported Outcomes for Sarecycline Effectiveness and Safety (PROSES)
A clinical trial, sponsored by Almirall, S.A..
- Completed
- Registry status
- 300
- Enrollment target
NCT04820673 is a clinical trial that has completed, run by Almirall, S.A.. The registered enrollment target is 300 participants.
The verdict
NCT04820673 has completed, sponsored by Almirall, S.A..
- COMPLETED
- Registry status
- 300 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the patient-reported outcomes (PROs) in terms of health-related quality of life (HRQoL) and signs of Acne Vulgaris (AV) among patients with moderate to severe non-nodular AV who are administered sarecycline (Seysara®) in real-world community practice settings in the United States (U.S). Investigator's Global Assessment (IGA) of AV and safety measures associated with use of sarecycline (Seysara®) will be assessed over the study observation period of 12 weeks. Clinicians will prescribe sarecycline (Seyara®) as per their own clinical judgment and standard practice.
Interventions
- DRUG Sarecycline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2021-03-09 |
| Est. Completion | 2022-05-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04820673
The ClinicalTrials.gov registry entry for NCT04820673 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Almirall, S.A., which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sarecycline is the first listed.
NCT04820673 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04820673 about?
NCT04820673 is a clinical study titled "Patient-reported Outcomes for Sarecycline Effectiveness and Safety (PROSES)". The purpose of this study is to evaluate the patient-reported outcomes (PROs) in terms of health-related quality of life (HRQoL) and signs of Acne Vulgaris (AV) among patients with moderate to severe non-nodular AV who are administered sarecycline (Seysara®) in real-world community practice settings...
What is the current status of trial NCT04820673?
This trial is currently completed. The enrollment target is 300 participants. The study started on 2021-03-09. Estimated completion is 2022-05-04.
What interventions are being tested in trial NCT04820673?
The interventions under investigation include: Sarecycline (DRUG).
Who is sponsoring clinical trial NCT04820673?
This trial is sponsored by Almirall, S.A., which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.